Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Subcutaneous LY2127399 in Rheumatoid Arthritis
2008-004875-23Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tabalumab in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Jan 2009; status: completed.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-004875-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004875-23.